Biote (BTMD) EBIT : $24.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biote EBIT?

Biote's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-1.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $24.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biote's annualized ROC % for the quarter that ended in Mar. 2024 was 110.79%. Biote's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -31.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biote's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 10.35%.

Biote EBIT Historical Data

The historical data trend for Biote's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote EBIT Chart

Biote Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

23.46

31.78

34.58

5.76

6.24

Biote Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial									-19.15	-9.63	25.05	10.88	-1.66

Competitive Comparison of Biote's EBIT

For the Medical Care Facilities subindustry, Biote's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biote's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biote's EV-to-EBIT falls into.

Biote EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.6 Mil.

Biote (NAS:BTMD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biote's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	41.708 * ( 1 - -74.79% )	/	( (59.709	+	71.888)	/ 2 )
=	72.9014132	/	65.7985
=	110.79 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	155.295	-	6.584	-	( 89.002	-	max(0, 22.215	-	122.343	+	89.002	))
=	59.709

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	160.108	-	9.433	-	( 78.787	-	max(0, 24.057	-	114.361	+	78.787	))
=	71.888

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Biote's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.656	/	( ( (3.095 + max(16.322, 0))	+	(4.393 + max(18.173, 0)) )	/	2 )
=	-6.656	/	( ( 19.417	+	22.566 )	/	2 )
=	-6.656	/	20.9915
=	-31.71 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.809	+	17.307	+	7.86)	-	(6.584	+	3.002	+	6.068)
=	16.322

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(8.022	+	18.917	+	8.635)	-	(9.433	+	2.876	+	5.092)
=	18.173

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biote's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	24.632	/	237.901
	=	10.35 %

Biote EBIT Related Terms

Thank you for viewing the detailed overview of Biote's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biote (BTMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038

Website

https://www.biote.com

Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.

Executives

Mary Elizabeth Conlon	officer: General Counsel	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg	10 percent owner	C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc	10 percent owner	757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar	officer: Chief Commercial Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp	10 percent owner	780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar	officer: Chief Financial Officer	7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer	director	C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris	director	11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer	director, officer: President and Director	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber	director, officer: Chief Executive Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038